Startups
MYND Life Sciences Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to its Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on historic research and development that commenced in 2016 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.
Overview
Location
Canada, British Columbia, Kelowna
Employees
11-50
Total raised
$2.45M
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 7, 2021 | Funding round | $2.4M |
Mentions in press and media 21
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 8, 2022 | MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial | Clinical validation of MYND Diagnostics' proprietary biomarkers in evaluating the efficacy of psilocybin-assisted psychotherapy in treatment-resistant depression VANCOUVER, BC, Feb. 8, 2022 /PRNewswire/ - MYND Diagnostics Inc., a wholly-own... |
| Jan 12, 2022 | MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia | MYND's Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) a biopharmaceutic... |
| Dec 15, 2021 | MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application | VANCOUVER, BC, Dec. 15, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (P... |
| Nov 30, 2021 | MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation | R&D project on psilocybin's benefits in treating diseases of the brain VANCOUVER, BC, Nov. 30, 2021 /CNW/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) is pleased and extremely grateful... |
| Oct 28, 2021 | MYND Life Sciences Announces Appointment of New Director | VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) announces the following changes to its Board of Directors. The Board has accepted the resignation of ... |
| Oct 13, 2021 | MYND Lifesciencs : Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial | Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression VANCOUVER, BC, Oct. 13, 2021 /PRNewswire/ - MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE: MYND) (OTC: MYNDF) is pl... |
| Oct 7, 2021 | MYND Lifesciencs : Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary - Diagnostics Ltd. | MYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other psychiatric disorders. VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ - MYND Life Sciences Inc. (CSE: MYND) (OTC: M... |
| Sep 9, 2021 | MYND Lifesciencs : Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offering | VANCOUVER, BC, Sept. 9, 2021 /PRNewswire/ - MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) ("MYND" or the "Company") is pleased to announce, further to its news release of August 26, 2021, the closing of its non-broker... |
| Sep 9, 2021 | MYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offering |
Show more
Reviews 0
FAQ about MYND Life Sciences Inc.
How much funding has MYND Life Sciences Inc. raised?
MYND Life Sciences Inc. has raised $2.45M in total across 2 funding rounds.
What funding rounds has MYND Life Sciences Inc. raised?
Parsers VC lists 2 funding rounds of MYND Life Sciences Inc., among them a funding round of $2.4M on Jan 7, 2021.
What has the press written about MYND Life Sciences Inc.?
Parsers VC has collected 21 articles mentioning MYND Life Sciences Inc., among them “MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial” (Feb 8, 2022) and “MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia” (Jan 12, 2022).
Is MYND Life Sciences Inc. still active?
Yes, MYND Life Sciences Inc. is active; its latest activity on Parsers VC dates from Mar 29, 2023.